-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 OFfi70V1eu6O32ilfEoQgcFrUbsQ1tz/tknRjQ+unngIvLnaz4SZv1g8xSjx0QK8
 eIrfJLUJQSBS1TVnWXY+UA==

<SEC-DOCUMENT>0001119774-07-000008.txt : 20070201
<SEC-HEADER>0001119774-07-000008.hdr.sgml : 20070201
<ACCEPTANCE-DATETIME>20070201075334
ACCESSION NUMBER:		0001119774-07-000008
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20070201
FILED AS OF DATE:		20070201
DATE AS OF CHANGE:		20070201

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COMPUGEN LTD
		CENTRAL INDEX KEY:			0001119774
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30902
		FILM NUMBER:		07569969

	BUSINESS ADDRESS:	
		STREET 1:		72 PINCHAS ROSEN ST
		STREET 2:		TEL AVIV
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			69512
		BUSINESS PHONE:		011-972-3-765-8585
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>sixkfebruary12007.htm
<DESCRIPTION>6-K - FEBRUARY 1, 2007
<TEXT>
<html>
<head>
<meta name=Generator content="Microsoft Word 11 (filtered)">
<title>6-kFebruary12007</title>

<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:Miriam;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0cm;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
h1
	{margin-top:3.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	text-align:center;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
h2
	{margin-top:3.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
h3
	{margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Times New Roman";
	font-weight:normal;}
h4
	{margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	page-break-after:avoid;
	font-size:13.0pt;
	font-family:"Times New Roman";
	font-weight:normal;}
h5
	{margin-right:0cm;
	margin-left:0cm;
	font-size:10.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
h6
	{margin:0cm;
	margin-bottom:.0001pt;
	line-height:150%;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{margin-top:6.0pt;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:0cm;
	text-align:center;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman";
	font-weight:bold;
	text-decoration:underline;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{margin:0cm;
	margin-bottom:.0001pt;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{margin:0cm;
	margin-bottom:.0001pt;
	line-height:150%;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:0cm;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0cm;
	margin-bottom:.0001pt;
	text-align:right;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{margin:0cm;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0cm;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{margin-top:6.0pt;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:0cm;
	text-indent:27.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{margin:0cm;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:10.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{margin:0cm;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{margin-top:6.0pt;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:0cm;
	text-align:justify;
	text-indent:27.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{margin-top:0cm;
	margin-right:2.9pt;
	margin-bottom:0cm;
	margin-left:36.0pt;
	margin-bottom:.0001pt;
	text-indent:30.95pt;
	line-height:16.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
a:link, span.MsoHyperlink
	{color:#000066;
	background:white;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0cm;
	margin-bottom:.0001pt;
	background:navy;
	font-size:10.0pt;
	font-family:Tahoma;}
p
	{margin-right:0cm;
	margin-left:0cm;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{margin:0cm;
	margin-bottom:.0001pt;
	font-size:8.0pt;
	font-family:Tahoma;}
span.tdfont1
	{font-family:Verdana;
	color:#484848;
	font-weight:normal;}
span.bold1
	{color:#34344C;
	font-weight:bold;}
span.contenttext1
	{font-family:Verdana;
	color:#333333;
	font-weight:normal;
	text-decoration:none none;}
p.ind1, li.ind1, div.ind1
	{margin-top:6.0pt;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:0cm;
	text-align:justify;
	text-indent:1.0cm;
	line-height:12.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.centhead, li.centhead, div.centhead
	{margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:12.0pt;
	margin-left:0cm;
	text-align:center;
	line-height:12.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
p.small, li.small, div.small
	{margin-right:0cm;
	margin-left:0cm;
	font-size:9.0pt;
	font-family:Tahoma;
	color:#555555;}
span.defaultlrg1
	{font-family:Arial;
	color:black;
	font-weight:normal;
	text-decoration:none none;}
p.headeredgarbold, li.headeredgarbold, div.headeredgarbold
	{margin:0cm;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:10.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
p.Headingnum1, li.Headingnum1, div.Headingnum1
	{margin-top:3.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:22.7pt;
	text-align:center;
	text-indent:-22.7pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
p.Headingnum2, li.Headingnum2, div.Headingnum2
	{margin-top:3.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:45.35pt;
	text-indent:-22.65pt;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
p.Headingnum3, li.Headingnum3, div.Headingnum3
	{margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:68.05pt;
	text-indent:-25.5pt;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Times New Roman";}
p.Headingnum4, li.Headingnum4, div.Headingnum4
	{margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:90.7pt;
	text-indent:-19.8pt;
	page-break-after:avoid;
	font-size:13.0pt;
	font-family:"Times New Roman";}
p.Indent0, li.Indent0, div.Indent0
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:14.4pt;
	margin-bottom:.0001pt;
	text-indent:-14.4pt;
	line-height:12.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.Indent1, li.Indent1, div.Indent1
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:14.4pt;
	margin-bottom:.0001pt;
	line-height:12.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.Indent2, li.Indent2, div.Indent2
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:28.8pt;
	margin-bottom:.0001pt;
	line-height:12.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.Indent3, li.Indent3, div.Indent3
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:57.6pt;
	margin-bottom:.0001pt;
	text-indent:-14.4pt;
	line-height:12.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.Tableheading, li.Tableheading, div.Tableheading
	{margin:0cm;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:12.0pt;
	border:none;
	padding:0cm;
	font-size:10.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
p.Tablewith1underline, li.Tablewith1underline, div.Tablewith1underline
	{margin-top:0cm;
	margin-right:2.85pt;
	margin-bottom:0cm;
	margin-left:2.85pt;
	margin-bottom:.0001pt;
	text-align:right;
	line-height:12.0pt;
	border:none;
	padding:0cm;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.Tablewith1underline0, li.Tablewith1underline0, div.Tablewith1underline0
	{margin-top:0cm;
	margin-right:-1.4pt;
	margin-bottom:0cm;
	margin-left:2.85pt;
	margin-bottom:.0001pt;
	text-align:right;
	line-height:12.0pt;
	border:none;
	padding:0cm;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.Tablewithdoubleline, li.Tablewithdoubleline, div.Tablewithdoubleline
	{margin-top:0cm;
	margin-right:2.85pt;
	margin-bottom:0cm;
	margin-left:2.85pt;
	margin-bottom:.0001pt;
	text-align:right;
	line-height:12.0pt;
	border:none;
	padding:0cm;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.Tablewithdoubleline0, li.Tablewithdoubleline0, div.Tablewithdoubleline0
	{margin-top:0cm;
	margin-right:-1.4pt;
	margin-bottom:0cm;
	margin-left:2.85pt;
	margin-bottom:.0001pt;
	text-align:right;
	line-height:12.0pt;
	border:none;
	padding:0cm;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.Tbalewithoutstyle, li.Tbalewithoutstyle, div.Tbalewithoutstyle
	{margin-top:0cm;
	margin-right:2.85pt;
	margin-bottom:0cm;
	margin-left:2.85pt;
	margin-bottom:.0001pt;
	text-align:right;
	line-height:12.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.Tablewithoutstyle, li.Tablewithoutstyle, div.Tablewithoutstyle
	{margin-top:0cm;
	margin-right:-1.4pt;
	margin-bottom:0cm;
	margin-left:0.1pt;
	margin-bottom:.0001pt;
	text-align:right;
	line-height:12.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.Index, li.Index, div.Index
	{margin:0cm;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman";}
@page Section1
	{size:612.0pt 792.0pt;
	margin:35.95pt 90.0pt 72.0pt 90.0pt;}
div.Section1
	{page:Section1;}
 /* List Definitions */
 ol
	{margin-bottom:0cm;}
ul
	{margin-bottom:0cm;}
- -->

</head>
<body lang=EN-US link="#000066" vlink=purple>
<div class=Section1>
<p align=center  Style="margin:0cm;text-align:center;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman""><b style='font-size:11.0pt'>FORM 6-K</b></p>
<p align=center  Style="margin:0cm;text-align:center;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman""><b style='font-size:11.0pt'>SECURITIES AND EXCHANGE COMMISSION</b></p>
<h3 Style="text-align:center;margin-top:12.0pt;  margin-bottom:3.0pt; margin-left:0cm; page-break-after:avoid; font-size:14.0pt;  font-weight:normal;font-family:"Times New Roman"" ><b style='font-size:11.0pt'>Washington</b><b style='font-size:11.0pt'>, D.C. 20549</b></h3>
<p align=center  Style="margin:0cm;text-align:center;margin-right:1.0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman""><b style='font-size:11.0pt'>&nbsp;</b></p>
<p align=center  Style="margin:0cm;text-align:center;margin-right:1.0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman""><b style='font-size:11.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Report
of Foreign Private Issuer</b></p>
<p align=center  Style="margin:0cm;text-align:center;margin-right:1.0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman""><b style='font-size:11.0pt'>&nbsp;</b></p>
<p  Style="margin:0cm;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p  Style="margin:0cm;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p align=center  Style="margin:0cm;text-align:center;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Pursuant to rule 13a-16 or 15d-16 of the Securities
Exchange Act of 1934</p>
<p align=center  Style="margin:0cm;text-align:center;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">for the month of February 2007</p>
<p  Style="margin:0cm;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p  Style="margin:0cm;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p align=center  Style="margin:0cm;text-align:center;margin-right:1.0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman""><u style='font-size:11.0pt'>Compugen Ltd.</u></p>
<p align=center  Style="margin:0cm;text-align:center;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">(Translation of registrant's name in English)</p>
<p align=center  Style="margin:0cm;text-align:center;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p align=center  Style="margin:0cm;text-align:center;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p align=center  Style="margin:0cm;text-align:center;margin-right:1.0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman""><u style='font-size:11.0pt'>72 Pinchas Rosen Street, Tel-Aviv 69512, Israel</u></p>
<p align=center  Style="margin:0cm;text-align:center;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">(Address of principal executive offices)</p>
<p align=center  Style="margin:0cm;text-align:center;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p  Style="margin:0cm;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p  Style="margin:0cm;text-align:justify;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F.</p>
<p align=center  Style="margin:0cm;text-align:center;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p align=center  Style="margin:0cm;text-align:center;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Form 20-F&nbsp;&nbsp;<u> X&nbsp;&nbsp;</u>             Form
40-F&nbsp;___</p>
<p  Style="margin:0cm;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</p>
<p  Style="margin:0cm;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p  Style="margin:0cm;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p  Style="margin:0cm;text-align:justify;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">On February 1, 2007 Compugen Ltd. (the
&quot;Registrant&quot;) issued a Press Release, filed as Exhibit 1 to this
Report on Form 6-K, which is hereby incorporated by reference herein.</p>
<p  Style="margin:0cm;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p align=center  Style="margin:0cm;text-align:center;margin-right:1.0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman""><b>&nbsp;</b></p>
<p align=center  Style="margin:0cm;text-align:center;margin-right:1.0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman""><b><u style='font-size:11.0pt'>SIGNATURE</u></b></p>
<p  Style="margin:0cm;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p  Style="margin:0cm;text-align:justify;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.</p>
<p  Style="margin:0cm;margin-left:1.0cm;margin-right:1.0cm;margin-top:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p align=center  Style="margin:0cm;text-align:center;margin-left:288.0pt;margin-right:1.0cm;margin-top:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">                                    </p>
<p  Style="margin:0cm;text-indent:225.0pt;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Compugen Ltd.</p>
<p  Style="margin:0cm;text-indent:225.0pt;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">(Registrant)</p>
<p  Style="margin:0cm;text-indent:225.0pt;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">By:    <u>/s/ Nurit Benjamini</u></p>
<p  Style="margin:0cm;text-indent:225.0pt;margin-right:1.0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Title:  Chief Financial Officer</p>
<p  Style="margin:0cm;text-indent:225.0pt;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Date: February
1, 2007</p>
<p align=center  Style="margin:0cm;text-align:center;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p align=center  Style="margin:0cm;text-align:center;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p align=center  Style="margin:0cm;text-align:center;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p align=center  Style="margin:0cm;text-align:center;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p align=center  Style="margin:0cm;text-align:center;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p Style="margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p Style="margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<b style='font-size:11.0pt;font-family:"Times New Roman"'><P Style="font-size:10.0pt;font-family:"Times New Roman"" align=center><B>__1__</B>&nbsp;</P><br clear=all
style='page-break-before:always'>
</b>
<p Style="margin:0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman""><b style='font-size:11.0pt'>&nbsp;</b></p>
<p Style="margin:0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman""><b style='font-size:11.0pt'>Exhibit 1</b></p>
<p align=center  Style="margin:0cm;text-align:center;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman""><img width=257
height=136 src="image001.jpg">                          </p>
<h3 Style="text-align:center;margin-top:12.0pt;  margin-bottom:3.0pt; margin-left:0cm; page-break-after:avoid; font-size:14.0pt;  font-weight:normal;font-family:"Times New Roman"" ><b>Compugen Ltd. to Review Fourth
Quarter and Full Year 2006 Results on Tuesday, February 6, 2007</b></h3>
<p align=center  Style="margin:0cm;text-align:center;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p align=center  Style="margin:0cm;text-align:center;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman""><i style='font-size:14.0pt'>Conference call to be held at 10:00 AM EST<br>
<br>
</i></p>
<p style='margin:0cm;margin-bottom:.0001pt;text-align:justify'><b style='font-size:11.0pt'>TEL AVIV, ISRAEL, February 1, 2007</b><Font
lang=DE style='font-size:11.0pt'> - Compugen Ltd. </FONT>(NASDAQ: CGEN) today announced that the Company&nbsp;&nbsp;plans
to host a live conference call and webcast at 10:00 AM EST to review fourth
quarter and full year 2006 results. The quarterly and full year results will be
released prior to the conference call.</p>
<p style='margin:0cm;font-size:11.0pt;margin-bottom:.0001pt;text-align:justify'>&nbsp;</p>
<p style='margin:0cm;font-size:11.0pt;margin-bottom:.0001pt;text-align:justify'>To access the conference call, please dial
1-888-281-1167 from the US or +972-3-918-0610 internationally.&nbsp;&nbsp;The
call will also be available via live webcast through Compugen`s Website,
located at www.cgen.com. <!-- Created Using Viltech Software --></p>
<p style='margin:0cm;margin-bottom:.0001pt;text-align:justify'><i style='font-size:11.0pt'>&nbsp;</i></p>
<p style='margin:0cm;font-size:11.0pt;margin-bottom:.0001pt;text-align:justify'>A replay of the conference call will be available
approximately two hours after the completion of the live conference call. To
access the replay, please dial 1-888-782-4291 from the US or +972-3-925-5901. The replay will be available until 12 noon EST on February 8, 2007. </p>
<p style='margin:0cm;font-size:11.0pt;margin-bottom:.0001pt;text-align:justify'>&nbsp;</p>
<p  Style="margin:0cm;text-align:justify;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman""><b style='font-size:11.0pt'>About
Compugen</b></p>
<p  Style="margin:0cm;text-align:justify;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Compugen`s
mission is to be the world leader in the discovery and licensing of product
candidates to the drug and diagnostic industry. The Company`s powerful
discovery engines enable the predictive discovery of numerous potential
therapeutics and diagnostic biomarkers. This capability results from the
Company`s decade-long pioneering efforts in the deeper understanding of
important biological phenomena at the molecular level through the incorporation
of ideas and methods from mathematics, computer science and physics into biology,
chemistry and medicine. To date, Compugen`s product discovery efforts and its
initial discovery engines have focused mainly within the areas of cancer,
immune-related and cardiovascular diseases. The Company's primary
commercialization pathway for its therapeutic and diagnostic product candidates
is to enter into milestone and revenue sharing out-licensing and joint
development agreements with leading companies. Compugen has established an
agricultural biotechnology affiliate - Evogene, and a small-molecule drug
discovery affiliate - Keddem Bioscience. For additional information, please
visit Compugen's corporate Website at www.cgen.com. </p>
<p  Style="margin:0cm;text-align:justify;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p  Style="margin:0cm;text-align:justify;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman""><b><i style='font-size:
11.0pt;layout-grid-mode:line'>Company contact:                                                        </i></b></p>
<p  Style="margin:0cm;layout-grid-mode:line;text-align:justify;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Nurit Benjamini</p>
<p  Style="margin:0cm;layout-grid-mode:line;text-align:justify;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Chief Financial Officer</p>
<p  Style="margin:0cm;layout-grid-mode:line;text-align:justify;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Compugen Ltd.</p>
<p  Style="margin:0cm;layout-grid-mode:line;text-align:justify;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Email: nurit@cgen.com  <!-- Created Using Viltech Software --></p>
<p  Style="margin:0cm;layout-grid-mode:line;text-align:justify;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Tel: +972-3-7658-525</p>
<p align=center  Style="margin:0cm;text-align:center;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">&nbsp;</p>
<P Style="font-size:10.0pt;font-family:"Times New Roman"" align=center><B>__2__</B>&nbsp;</P></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image001.jpg
<DESCRIPTION>COMPUGEN LOGO
<TEXT>
begin 644 image001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#__@`<4V]F='=A<F4Z($UI8W)O<V]F="!/
M9F9I8V7_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-#AT5%A$8(Q\E)"(?(B$F
M*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_VP!#`0H+"PX-#AP0$!P[
M*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SO_P``1"`"(`0$#`2(``A$!`Q$!_\0`'``!``,!`0$!`0``````
M``````4&!P0#"`$"_\0`21```00!`@(%!0P%"@<``````0`"`P0%!A$2(0<3
M,4%1%")A<8$5%C)65Y&2E*'1TN$C,U*3TQ<E0E-B9G*DL<%4@J*RPN+P_\0`
M&0$!`0$!`0$```````````````$"`P0%_\0`+!$!``(!`@0$!04!````````
M``$"$0,$$B$QT4%1H?`3%&&QP3)QD;+A\O_=``0`*/_:``P#`0`"$0,1`#\`
MV9$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1
M$!$1`7X2&@DG8#F2O":[6@)9)9@CD`^"^0!5N6?4CY7.CU)@HV$^:SJ2>$>&
M_'S6ZUR.J?7.$@F?$77'EAV+HZ<KFGU$-YK^/?\`8/\`9O\`U"7\*Y>MU/\`
M&C!?5S^->5F]J&G7?8L:KP+(HQNYWDY.P]CUUBE/<_XCO]_V#_9O_4)?PK^9
M.D##L;O'7R<SB0`QE"3<_.`%4;NLK%RJZ#W\T:X=VR08V5KP/0>>RMFB\->J
M5SD+VH+>5%A@,'6%[6-8>>_"X]I]*U;3I2,VCW_`LL$AF@9*Z)\1>T'@?MQ-
M]!V[UZ(B\JB(B`B(@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("X,M?MT*[9
M*>,FR$CG;=7$]K=AXDN*[U7=4P5XFLOW-09'%0-`C/DKO,))/,^:>?<M4C-L
M"%LUVW+#[-KHV?--(=WR22PN<X^LE>7N=5^3`?3A^]>/NCI_Y0<Q](_PT]T=
M/_*#F/I'^&O9BWE_9'J<?4:"3T8M`':3)`/]U"6:&9=9D=4T)@XX.+]&V01N
M<!Z2'C<KMR%K3-K'SPSZVR]R-S#O7+_UG?P\V=ZIVVC?^#S_`-.+[EUTXGWG
M\RBU8O$YFSE:L-W1^"BK/E`E>V-A+6]^VSSS6K-:&M#6@``;`#N6$8Z]I/%Y
M*O?K4\]UU>02,XG1;$CN/+L6RX+/4=0XYMVB\[=CXW#9T;O`A>?<UMRGP]_6
M5A)HB+R*_]#9D1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0%^$;]J_4
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M<2T/`Y@;@'O7>JCT>5IZ^,M=?@6X7BFY0@O/'YH\[SB?5[%;E\[4B*VF(:$1
M%@$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`7G-/%7B=+/*R*-HW<][@T
M#UDJ-RMS.PRAF*Q,%IO]*2:T(Q[``2HN>SJVS'U=C3.+E9OOPR7>(?,6+<4S
MS_,#VR6J,+;INAI:LH4I7$?IA(QY`]`)V4+[HL^4^O\`NH%V]3J'XFX3ZR/P
M*-FSLE>9T,^&TM'(P[.8[(,!:?`^8O16L=(_"/7W19\I]?\`=0+ARFI8<7$U
MYZ0I;;G'81U*<,CO6>X?.HZ]D<W:L%]:[I.E'W1QRPN^<N!W7E7&JK<[8*N5
MT[/,[X,<?D[G'V!B[12.LX].R(G(9+`Y2X^W=U'FY)G[;N%9C1R[.0?L%UX'
M3V+U)<\EQN7SCR.;Y75VAD8])X_L5TP.EM1OE$N>NT8XFG]17IPES_6[@Y#U
M*Z05H*S"RO#'$TG<B-H:"?8LWW$5C%??HN'/B,7!AL7!CZY<YD+=N)YW<X]Y
M/I)7:B+PS.9S*B(B@(B("(B`B(@(B("(B#__T=F1$0$1$!$1`1$0$1$!4C/9
M3"9.YP7(-0@UR6`58IF,)WYGS>WUJ[JHVI,W%;E8=9XJ#9YVBDK,XF#N!W?X
M+KI=??807#I?^HU7_F?O3ATO_4:K_P`S]ZF/*,U\>L/]69^-/*,U\>L/]69^
M->C/U]9[(K.4EQD,<?N5AM37G.)#Q+8LQ!H^W=07DM/Y/\E]9F_`K!JM\H=7
MGR6O&C?=C!CX#MX^<&/^TJ-PE&/.Y2*A2UOE)97[N+>IE;YHYGF7\EWI.*Y[
MHZ]-:4HY^X63:0LX^M'^LFGNR@^IK2T;E:3A-.8G3T!BQM-D/%\)YYO=ZW'F
M5W5J\=.K'7C+N")H:"]Q<=AXD]JRK5G2E>DNRT\"]L%>,EILEH<Z0]Y;OR`^
MU>;.IKVQ7HO1K:+"<AF=<85M2S?RER$6V=9"'2`[CEVM[NT<BK_HS71R>FKM
M[,O8U^-VZV5@V#VD<CMX]VWJ6;[:U:\43DRNZ+%,OTE:BS-T08ISJ44C^&**
M%H=(_<[#<GO]2X9]4:TP&2=7N9.W'8CV+HIR'C8C<<N86XVEYZS&3+>45'BU
MQ+>Z-KF<:&P786F$\(W`EY`$;_X@50:6OM7S7H(F9":RYTC0(6Q,WDY_!Y-[
MUBFVO;/T,MV18)E-;:M?DI>OR-BG+&\M->/S!&1W;?>I#(Z_U;8P--_GU(7;
ML==C9L;#AX'NV'AZ5OY2_+G!EM:+*.C75N:O:B]S+]R2Y!+$YP,O-S".>^_A
MW*)S_2#J%FH+[*.4=%59.YD3!&P@-!V[QZ%GY6_'-<F6VHL-R6KM;G%4[-BS
M8JU901%.Q@89CXDC\AR5HZ,]99+)W+&,RM@V0R$S1S/'G``@$$]_:EMM:M>+
M)EI2+"+G2+J=]R=\&5?'"9'&-@B9YK=^0[/!6G6.J<YA,#@88<@YE^Q!UMF3
M@:2[D.6VVPYD_,D[6\3$9ZF6G(LNT#JW,7K.1NYO)ODH4*O6/!8T#<GEV`=P
M*KN:Z1M0Y>Z[R*U)1KEVT4,')VW=N>TE(VMYM-?(RW-%AUW6.M\,R/'7K4U:
M=OZ0.EC:9'-/8"2#N.1]*M.@M5Y*QCLME\_D72TZ36@;L:.?,G;8#<]@]JEM
MM:M>+,&6D(L7N](&J-2Y5M+#%U1LS^&&&$#C/^)Q]'AL%QV-3ZTTQEW5KV2F
M,\6Q=%,X2L<"-Q_\%J-I?IF,^1ENB+/M5ZVM1Z&QF4QLIJV<@\=@#N$`'B',
M>(V52P^NM9V;Q97FER+Q&XB$0M([/A'8`[#M6:[:]J\1EMR+Y^&N]4LM>4^[
M-@N!WX#MP>KAVVV6[XVR^[BZEN1H8^>%DCFCN)`*SJZ%M+&2)=2(BX**MZ@Q
MD/E+;$&D:F8EFWZV1[HV.:1MMOQ#G^2LB\;=<6ZLM=TDD0D:6\<3^%[?2#W%
M:K;AG(I?D$GR9TOW\'W)Y!)\F=+]_!]REO>8WXPY[Z]^2>\QOQASWU[\EW^)
M7S^_=$%>QN0DIR,Q_1[0JV2!P2O?`]K>?>W;FO?05?)LR-M^2HXBN6QAK#1;
M%Q[[\P>`D[<AVJ6]YK?C#GOKWY+TP&C<;IR_9O4YK4DUINTKIY`[BY[[]@Y[
MJSJ5X)COW'3JN:6OI3*2P;]8VJ_;;M')?/\`BX8I\K3AG>UD+YV->YQV`:7#
M??V+Z5DC9+&Z.1H>QX+7-(W!![0L]R'0]C9[#I*.1GJ1N._5.8)`WT`[@[+6
MVUJ4B8L3#^=6:\T]7RWD,N$@S`KM`$W$PM:3VM&X/H49JB[!=Z-H[V/PS,5#
M<NM#V1@?I&M#MG'8#EN/L4SC.B'$5)FR7KD]UK3N(MA&P^O;F?G5SO8BAD<6
M_&6:S'5',#.K`V#0.S;;LV[DG4TJ37AYX&&Z#DI0ZQI3Y">."&+B?QR.V:'!
MIVY^M<^L,M'FM4WK\+N*%S^&)WBUHV!]NV_M5]L=#5-TI-;,3QQD\FR1->1[
M=PI7!]%V$Q-AEFR^7(31G=O7`!@/CPCM]NZ]$[C2BW'GGA,2I&5K38/HPH4I
MVF.;)VS9<P\B&`<M_P#I*\NC"HV?5S;4@_1TH'S.)[N7"/\`5:5JO1%?5EBO
M+9O3UQ786M9&&D'<\SS]07A@^CZG@:N1AKW[#WWX>I,CFMWC'/LV'I^Q<OF*
M_#F/&5PQ7(VW7\C:N/YNGE?(?:25;]>_S=@=-X,<C#5ZZ0?VG;?[\2LL70[B
MXY6/.4MN#7`\):S8[=W8I34G1W4U+ECD+&1LPGJVQMCC:WA:!ZQZ5TG<:<VK
MSY0F%)Z,FBD,WG'CS:5,AI/B=S_X_:J*29'%SSS<=R?6M6U'@ZNA^CR_3JV)
M)G9"=C"^0`'GMRY=VS3\ZH.DL/'GM34\=,'&&0DR\)V/"`2>:ZZ=XGBU/#L+
M#TB9W&W*.(Q.)LQV(:<7$]T9W:#PAK1Z]M_G7+HR*6CA-0Y[A(9!3->-WB]^
MW9ZN7SJT,Z&J0L<3\Q8=!O\``$30[;PXOR5S][6+;IU^!CK]72?&6%K3SY_T
MM_'?GNO/;7TZTBE>9A\]TF0ONUV6'B.$RM$CSV-;N-S\RL72%FZN;U,9*,PE
MJUX6PQO;V';<G;VG[%<(.ANBRR'3Y>Q+`#OU;8PUQ'AQ?DNBUT08FQ:DEBOV
M:['NW;$QK>%@\!N%UG<:4VBV3$J?3KRU.B?(6V`CRV]'&XC]AO\`[*$TM8HU
M-3X^SD9!'5AF#WN()`V&XY#T[+4,_/BM#:2IX2UCY<G2L<<;B7!I)WXMSZ>?
M+;P5"QS]!S6WNNP9:M$UO$UAF$@<?V?-;O\`:KIWXJVG$XD<^N,[#J'4\]RJ
MXNK-:V*(D;;@=^WI)*E+5>6AT0U"T$"_?ZR0^(`(;_V@JK]2[+9DPXZKPFS,
M1!`S^B">0]@[UO?O9H3Z6AP%R/K:\<+(R0=CQ`?"![COS4UKUTHI!#$-,85F
M<R,E=^5BQG5Q%XED.V_,#8<QW%=$N)T]U[F.U6^5X=P\3:$CN(]G([\U=)>A
MBJZ0]5FIFQ[\FO@:XCV[C_13FGNC3"X*TRY(Z6]9C.['3;!K#XAH[_7NI;<T
MZQ;T,,_U_$,7#A,`R4R-HU"]SBWAW<\^'=V+KZ/_`.;=.ZCSAY&*OU,9_M$$
M_P"O"KEJ'HVIZBS,V3L9.S&^4-'`QK=F@#;EN%[PZ`IP:2GT['>L-BL3=;)-
MPMXSS'+LVVY!<YUZ?#BN?W_)AB5"JZ]?K5&\W3RMC'M("^EHHVPQ,B8-FL:&
MM'@`J3A^BS'8C+ULBW(69G5G\;6/:W8GN[`KRN6YU:ZDQPK$"(B\BB(B#__2
MV9$1`1$0$1$!$1`1$0$1$!$1!&YG`8W4$$<&3KF>.-W&UO&YNQVVWY%<N)T;
M@<'=\LQU'J9^$LX^L<[D>WM*G$6HO:(QGD"(BR"(B#DR6,HY>FZID*T=B!QW
M+'CO\1X%5EW17I5S^(5K#1^R+#ME<46ZZEZ_ID1&&TMA<`2[&T(X9"-C*=W/
M(_Q'FI=$69F9G,@B(H"(B`B(@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("(
5B`B(@(B("(B`B(@(B("(B`B(@__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
